Conflict of interest declaration: Tom Jefferson

Updated on: 7 July 2021

Roles in: Acute Respiratory Infections Group

1. In the past 36 months have you accepted the following from a commercial organisation with a financial interest in the broad topic area of the CRG?

a) Support for attending meetings, including sabbaticals and study tours (this covers travel, accommodation and/or hospitality)?
No

b) Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events?
No

c) Fees for organising education?
No

d) Grants and contracts?
Yes - This is a general statement giving details over and beyond the required time span: TJ was in receipt of a Cochrane Methods Innovations Fund grant to develop guidance on the use of regulatory data in Cochrane reviews (2015-018). In 2014???2016, TJ was a member of three advisory boards for Boehringer Ingelheim. TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine. TJ is occasionally interviewed by market research companies about phase I or II pharmaceutical products for which he receives fees (current). TJ was a member of three advisory boards for Boehringer Ingelheim (2014-16) TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine (2015-2017). TJ is a relator in a False Claims Act lawsuit on behalf of the United States that involves sales of Tamiflu for pandemic stockpiling. If resolved in the United States??? favor, he would be entitled to a percentage of the recovery????. TJ is co-holder of a Laura and John Arnold Foundation grant for development of a RIAT support centre (2017-2020) and Jean Monnet Network Grant, 2017-2020 for The Jean Monnet Health Law and Policy Network. TJ is an unpaid collaborator to the project Beyond Transparency in Pharmaceutical Research and Regulation led by Dalhousie University and funded by the Canadian Institutes of Health Research (2018-2022). TJ consults for Illumina LLC on next generation gene sequencing (2019-). TJ was the consultant scientific coordinator for the HTA Medical Technology programme of the Agenzia per i Serivizi Sanitari Nazionali (AGENAS) of the Italian MoH (2007-2019). Tom Jefferson competing interests statement 26 October 2019: TJ was in receipt of a Cochrane Methods Innovations Fund grant to develop guidance on the use of regulatory data in Cochrane reviews (2015-018). In 2014???2016, TJ was a member of three advisory boards for Boehringer Ingelheim. TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine. TJ is occasionally interviewed by market research companies about phase I or II pharmaceutical products for which he receives fees (current). TJ was a member of three advisory boards for Boehringer Ingelheim (2014-16) TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine (2015-2017). TJ is a relator in a False Claims Act lawsuit on behalf of the United States that involves sales of Tamiflu for pandemic stockpiling. If resolved in the United States??? favor, he would be entitled to a percentage of the recovery????. TJ is co-holder of a Laura and John Arnold Foundation grant for development of a RIAT support centre (2017-2020) and Jean Monnet Network Grant, 2017-2020 for The Jean Monnet Health Law and Policy Network. TJ is an unpaid collaborator to the project Beyond Transparency in Pharmaceutical Research and Regulation led by Dalhousie University and funded by the Canadian Institutes of Health Research (2018-2022). Tom Jefferson competing interests statement April 6, 2018: TJ was a corecipient of a UK National Institute for Health Research grant (HTA ??? 10/80/01 Update???and amalgamation of two Cochrane reviews: neuraminidase inhibitors for preventing and treating influenza in healthy adults and children; https://www.journalslibrary.nihr.ac.uk/programmes/hta/108001/). TJ was also in receipt of a Cochrane Methods Innovations Fund grant to develop guidance on the use of regulatory data in Cochrane reviews. TJ is occasionally interviewed by market research companies about phase I or II pharmaceutical products. In 2011???2014, TJ acted as an expert witness in a litigation case related to the antiviral oseltamivir, in two litigation cases on potential vaccine-related damage and in a labour case on influenza vaccines in healthcare workers in Canada. He has acted as a consultant for Roche (1997???1999), GSK (2001???2002), Sanofi-Synthelabo (2003) and IMS Health (2013). In 2014???2016, TJ was a member of three advisory boards for Boehringer Ingelheim. TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine. TJ has a potential financial conflict???of interest on the drug oseltamivir. TJ was a cosignatory of a complaint to the European Ombudsman on maladministration in relation to the EMA investigation of possible harms from HPV vaccines. TJ is co-holder of a Laura and John Arnold Foundation grant for development of a RIAT support centre (2017-2020) and Jean Monnet Network Grant, 2017-2020 for The Jean Monnet Health Law and Policy Network. TJ is an unpaid collaborator to the project Beyond Transparency in Pharmaceutical Research and Regulation led by Dalhousie University and funded by the Canadian Institutes of Health Research (2018-2022). TJ is Director Medical Affairs for BC Solutions, a market access company for medical devices in Europe.

e) Funds for a member of staff?
No

f) Fees for consulting?
Yes - See above

g) Royalty or licences payments?
Yes - See above

h) Payment for expert testimony?
No

i) Payment for a fellowship?
No

j) Payment for participation on a Data Safety Monitoring Board, Advisory Board, or Guideline Panel?
No

k) Payment for a leadership or other fiduciary role in other board, society, committee, or advocacy group?
No

2. In the past 36 months have you, your spouse/partner or an immediate family member been employed by or do you or they own a commercial organization with a financial interest in the broad topic area of the CRG?
No

3. Do you own stocks or shares in a commercial organization with a financial interest in the broad topic area of the CRG?
No

4. Do you hold any patents (planned, issued or pending) for products relevant to the broad topic area of the CRG?
No

5. Do you have any other competing interests (financial or non-financial)?
Yes - See https://restoringtrials.org/competing-interests-tom-jefferson/